ENZANDRO 40

Enzandro 40mg capsule contains Enzalutamide as its active ingredient and is classified under androgen receptor inhibitors, a group of antineoplastic (anti-cancer) drugs. It is specifically indicated for the treatment of advanced stages of prostate cancer in patients whose disease has progressed despite undergoing surgical or hormonal therapies. By inhibiting the action of androgens (male hormones) that fuel prostate cancer growth, Enzandro helps to slow down or stop the progression of the disease.

This medication should not be taken if you are known to be allergic to Enzalutamide or any of the other components of the capsule. During the course of treatment, your doctor may recommend regular monitoring through blood tests, including Prostate-Specific Antigen (PSA) levels. PSA is a protein produced by the prostate, and its levels can reflect disease progression or response to therapy. Additional monitoring may include liver function tests and a complete blood count (CBC) to identify and manage potential side effects early.

Since Enzandro 40mg capsule can increase the risk of seizures, it should be used with caution in patients with a personal or family history of seizures or conditions that increase seizure risk. Consumption of grapefruit or grapefruit juice should be avoided, as it can interfere with the metabolism of the drug and potentially raise its concentration in the blood, increasing the risk of side effects.

This medication is not suitable for use during pregnancy due to the risk of harm to the unborn child. It may also impair fertility, so it is important to discuss any fertility-related concerns with your doctor prior to beginning treatment. Both male and female patients are advised to use effective contraceptive measures throughout the treatment and for at least three months following the last dose to prevent unintended pregnancy. Always follow your healthcare provider’s guidance carefully during treatment with Enzandro 40mg